QDEL — QuidelOrtho Corp

Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1906324 ·
Last close
$13.13
Market Cap
$895.35M
52W High
$18.70
52W Low
$9.92
ADV30
2,018,812
Next earnings
2026-07-29
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 619,800,000 263,800,000 -27,400,000 -91,800,000 5,628,700,000 140,400,000 3,777,300,000
Dec 2025 723,600,000 320,400,000 -37,300,000 -130,700,000 5,769,300,000 169,800,000 3,848,800,000
Sep 2025 699,900,000 335,600,000 45,200,000 -733,000,000 5,675,100,000 98,100,000 3,638,700,000
Jun 2025 613,900,000 274,900,000 -1,800,000 -255,400,000 6,379,100,000 151,700,000 3,586,400,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$6,600,000
Investing CF
$-170,500,000
Financing CF
$175,800,000
CapEx
$-166,000,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-17.82
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,087,800,000
Inventory
$611,500,000
Receivables
$486,700,000
ST Investments
$0
EBIT TTM
$-989,600,000
Pretax Income TTM
$-1,178,400,000
Interest Exp TTM
$188,800,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,657,200,128
EBITDA
$491,700,000
Free Cash Flow
$208,575,008
Enterprise Value
$3,697,156,864
Total Cash
$140,400,000
Total Debt
$2,874,700,032
Shares Out
68,190,989
Trailing EPS
$-17.85
Book Value
$27.19
ROE
-49.9%
ROA
0.5%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,730,200,000 54,800,000 -1,131,800,000 5,769,300,000 3,848,800,000 105,200,000
Dec 2024 2,782,900,000 45,800,000 -2,052,000,000 6,423,600,000 3,439,100,000 83,000,000
Dec 2023 2,997,800,000 257,000,000 -10,100,000 8,563,100,000 3,557,200,000 280,200,000
Dec 2022 3,266,000,000 982,500,000 548,700,000 8,855,800,000 3,921,200,000 885,300,000

TTM Snapshot

Revenues TTM
$2,764,700,000
NetIncome TTM
$202,300,000
OpCashFlow TTM
$0
Assets (Latest)
$6,423,600,000
Forward EPS
$2.44

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $25.00 · spot: $13.13 · call volume: 51 · put volume: 271
Expected Move to 2026-12-18: ±$7.11 (54.15%) — implied range $6.02$20.24 · ATM straddle on $12.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ABSI Absci Corp $1.12B $7.18
NNNN Anbio Biotechnology $696.11M $15.86
ACHV ACHIEVE LIFE SCIENCES, INC. $550.25M $5.36
MYGN MYRIAD GENETICS INC $413.68M $4.38
NEOG NEOGEN CORP $1.94B $8.93

News headlines (Yahoo Finance, 1h cache)

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
2026-06-17 15:16 · Yahoo
Is the Options Market Predicting a Spike in QuidelOrtho Stock?
2026-06-12 12:34 · Yahoo
3 Value Stocks We Approach with Caution
2026-06-11 12:33 · Yahoo
1 Stock Under $50 with Exciting Potential and 2 Facing Challenges
2026-06-08 16:21 · Yahoo
A Look At QuidelOrtho (QDEL) Valuation After Recent Share Price Rebound And Longer Term Weakness
2026-06-08 02:09 · Yahoo
QuidelOrtho (QDEL) Up 24.1% Since Last Earnings Report: Can It Continue?
2026-06-04 15:30 · Yahoo
QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk
2026-06-03 17:44 · Yahoo
QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies
2026-06-02 11:12 · Yahoo
McIntyre Partnerships’ Analysis on QuidelOrtho Corporation (QDEL)
2026-06-01 16:49 · Yahoo
When Blood Compatibility Becomes a Pregnancy Risk
2026-05-21 13:18 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.